Global COVID-19 Neutralizing Antibody Drugs Market Growth 2022-2028
The global market for COVID-19 Neutralizing Antibody Drugs is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC COVID-19 Neutralizing Antibody Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States COVID-19 Neutralizing Antibody Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe COVID-19 Neutralizing Antibody Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China COVID-19 Neutralizing Antibody Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key COVID-19 Neutralizing Antibody Drugs players cover Tychan, AstraZeneca, Molecular Partners
AG/诺华, Eli Lilly and Regeneron Pharmaceuticals and etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global COVID-19 Neutralizing Antibody Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global COVID-19 Neutralizing Antibody Drugs market, with both quantitative and qualitative data, to help readers understand how the COVID-19 Neutralizing Antibody Drugs market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the COVID-19 Neutralizing Antibody Drugs market and forecasts the market size by Type (ACE2 Fusion Protein and Neutralizing Antibody,), by Application (Hospital and Clinic.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
ACE2 Fusion Protein
Neutralizing Antibody
Segmentation by application
Hospital
Clinic
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Tychan
AstraZeneca
Molecular Partners
AG/诺华
Eli Lilly
Regeneron Pharmaceuticals
Abpro
Chapter Introduction
Chapter 1: Scope of COVID-19 Neutralizing Antibody Drugs, Research Methodology, etc.
Chapter 2: Executive Summary, global COVID-19 Neutralizing Antibody Drugs market size (sales and revenue) and CAGR, COVID-19 Neutralizing Antibody Drugs market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: COVID-19 Neutralizing Antibody Drugs sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global COVID-19 Neutralizing Antibody Drugs sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global COVID-19 Neutralizing Antibody Drugs market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Tychan, AstraZeneca, Molecular Partners
AG/诺华, Eli Lilly, Regeneron Pharmaceuticals and Abpro, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global COVID-19 Neutralizing Antibody Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for COVID-19 Neutralizing Antibody Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for COVID-19 Neutralizing Antibody Drugs by Country/Region, 2017, 2022 & 2028
2.2 COVID-19 Neutralizing Antibody Drugs Segment by Type
2.2.1 ACE2 Fusion Protein
2.2.2 Neutralizing Antibody
2.3 COVID-19 Neutralizing Antibody Drugs Sales by Type
2.3.1 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global COVID-19 Neutralizing Antibody Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global COVID-19 Neutralizing Antibody Drugs Sale Price by Type (2017-2022)
2.4 COVID-19 Neutralizing Antibody Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 COVID-19 Neutralizing Antibody Drugs Sales by Application
2.5.1 Global COVID-19 Neutralizing Antibody Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global COVID-19 Neutralizing Antibody Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global COVID-19 Neutralizing Antibody Drugs Sale Price by Application (2017-2022)
3 Global COVID-19 Neutralizing Antibody Drugs by Company
3.1 Global COVID-19 Neutralizing Antibody Drugs Breakdown Data by Company
3.1.1 Global COVID-19 Neutralizing Antibody Drugs Annual Sales by Company (2020-2022)
3.1.2 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Company (2020-2022)
3.2 Global COVID-19 Neutralizing Antibody Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global COVID-19 Neutralizing Antibody Drugs Revenue by Company (2020-2022)
3.2.2 Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Company (2020-2022)
3.3 Global COVID-19 Neutralizing Antibody Drugs Sale Price by Company
3.4 Key Manufacturers COVID-19 Neutralizing Antibody Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers COVID-19 Neutralizing Antibody Drugs Product Location Distribution
3.4.2 Players COVID-19 Neutralizing Antibody Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for COVID-19 Neutralizing Antibody Drugs by Geographic Region
4.1 World Historic COVID-19 Neutralizing Antibody Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global COVID-19 Neutralizing Antibody Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global COVID-19 Neutralizing Antibody Drugs Annual Revenue by Geographic Region
4.2 World Historic COVID-19 Neutralizing Antibody Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global COVID-19 Neutralizing Antibody Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global COVID-19 Neutralizing Antibody Drugs Annual Revenue by Country/Region
4.3 Americas COVID-19 Neutralizing Antibody Drugs Sales Growth
4.4 APAC COVID-19 Neutralizing Antibody Drugs Sales Growth
4.5 Europe COVID-19 Neutralizing Antibody Drugs Sales Growth
4.6 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Growth
5 Americas
5.1 Americas COVID-19 Neutralizing Antibody Drugs Sales by Country
5.1.1 Americas COVID-19 Neutralizing Antibody Drugs Sales by Country (2017-2022)
5.1.2 Americas COVID-19 Neutralizing Antibody Drugs Revenue by Country (2017-2022)
5.2 Americas COVID-19 Neutralizing Antibody Drugs Sales by Type
5.3 Americas COVID-19 Neutralizing Antibody Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC COVID-19 Neutralizing Antibody Drugs Sales by Region
6.1.1 APAC COVID-19 Neutralizing Antibody Drugs Sales by Region (2017-2022)
6.1.2 APAC COVID-19 Neutralizing Antibody Drugs Revenue by Region (2017-2022)
6.2 APAC COVID-19 Neutralizing Antibody Drugs Sales by Type
6.3 APAC COVID-19 Neutralizing Antibody Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe COVID-19 Neutralizing Antibody Drugs by Country
7.1.1 Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2017-2022)
7.1.2 Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2017-2022)
7.2 Europe COVID-19 Neutralizing Antibody Drugs Sales by Type
7.3 Europe COVID-19 Neutralizing Antibody Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa COVID-19 Neutralizing Antibody Drugs by Country
8.1.1 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Type
8.3 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of COVID-19 Neutralizing Antibody Drugs
10.3 Manufacturing Process Analysis of COVID-19 Neutralizing Antibody Drugs
10.4 Industry Chain Structure of COVID-19 Neutralizing Antibody Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 COVID-19 Neutralizing Antibody Drugs Distributors
11.3 COVID-19 Neutralizing Antibody Drugs Customer
12 World Forecast Review for COVID-19 Neutralizing Antibody Drugs by Geographic Region
12.1 Global COVID-19 Neutralizing Antibody Drugs Market Size Forecast by Region
12.1.1 Global COVID-19 Neutralizing Antibody Drugs Forecast by Region (2023-2028)
12.1.2 Global COVID-19 Neutralizing Antibody Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global COVID-19 Neutralizing Antibody Drugs Forecast by Type
12.7 Global COVID-19 Neutralizing Antibody Drugs Forecast by Application
13 Key Players Analysis
13.1 Tychan
13.1.1 Tychan Company Information
13.1.2 Tychan COVID-19 Neutralizing Antibody Drugs Product Offered
13.1.3 Tychan COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Tychan Main Business Overview
13.1.5 Tychan Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca COVID-19 Neutralizing Antibody Drugs Product Offered
13.2.3 AstraZeneca COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Molecular Partners
AG/诺华
13.3.1 Molecular Partners
AG/诺华 Company Information
13.3.2 Molecular Partners
AG/诺华 COVID-19 Neutralizing Antibody Drugs Product Offered
13.3.3 Molecular Partners
AG/诺华 COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Molecular Partners
AG/诺华 Main Business Overview
13.3.5 Molecular Partners
AG/诺华 Latest Developments
13.4 Eli Lilly
13.4.1 Eli Lilly Company Information
13.4.2 Eli Lilly COVID-19 Neutralizing Antibody Drugs Product Offered
13.4.3 Eli Lilly COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Eli Lilly Main Business Overview
13.4.5 Eli Lilly Latest Developments
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Information
13.5.2 Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Product Offered
13.5.3 Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Regeneron Pharmaceuticals Main Business Overview
13.5.5 Regeneron Pharmaceuticals Latest Developments
13.6 Abpro
13.6.1 Abpro Company Information
13.6.2 Abpro COVID-19 Neutralizing Antibody Drugs Product Offered
13.6.3 Abpro COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Abpro Main Business Overview
13.6.5 Abpro Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. COVID-19 Neutralizing Antibody Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. COVID-19 Neutralizing Antibody Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of ACE2 Fusion Protein
Table 4. Major Players of Neutralizing Antibody
Table 5. Global COVID-19 Neutralizing Antibody Drugs Sales by Type (2017-2022) & (K Units)
Table 6. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2017-2022)
Table 7. Global COVID-19 Neutralizing Antibody Drugs Revenue by Type (2017-2022) & ($ million)
Table 8. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2017-2022)
Table 9. Global COVID-19 Neutralizing Antibody Drugs Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global COVID-19 Neutralizing Antibody Drugs Sales by Application (2017-2022) & (K Units)
Table 11. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2017-2022)
Table 12. Global COVID-19 Neutralizing Antibody Drugs Revenue by Application (2017-2022)
Table 13. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2017-2022)
Table 14. Global COVID-19 Neutralizing Antibody Drugs Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global COVID-19 Neutralizing Antibody Drugs Sales by Company (2020-2022) & (K Units)
Table 16. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Company (2020-2022)
Table 17. Global COVID-19 Neutralizing Antibody Drugs Revenue by Company (2020-2022) ($ Millions)
Table 18. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Company (2020-2022)
Table 19. Global COVID-19 Neutralizing Antibody Drugs Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers COVID-19 Neutralizing Antibody Drugs Producing Area Distribution and Sales Area
Table 21. Players COVID-19 Neutralizing Antibody Drugs Products Offered
Table 22. COVID-19 Neutralizing Antibody Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global COVID-19 Neutralizing Antibody Drugs Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share Geographic Region (2017-2022)
Table 27. Global COVID-19 Neutralizing Antibody Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global COVID-19 Neutralizing Antibody Drugs Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country/Region (2017-2022)
Table 31. Global COVID-19 Neutralizing Antibody Drugs Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas COVID-19 Neutralizing Antibody Drugs Sales by Country (2017-2022) & (K Units)
Table 34. Americas COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2017-2022)
Table 35. Americas COVID-19 Neutralizing Antibody Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2017-2022)
Table 37. Americas COVID-19 Neutralizing Antibody Drugs Sales by Type (2017-2022) & (K Units)
Table 38. Americas COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2017-2022)
Table 39. Americas COVID-19 Neutralizing Antibody Drugs Sales by Application (2017-2022) & (K Units)
Table 40. Americas COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2017-2022)
Table 41. APAC COVID-19 Neutralizing Antibody Drugs Sales by Region (2017-2022) & (K Units)
Table 42. APAC COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2017-2022)
Table 43. APAC COVID-19 Neutralizing Antibody Drugs Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region (2017-2022)
Table 45. APAC COVID-19 Neutralizing Antibody Drugs Sales by Type (2017-2022) & (K Units)
Table 46. APAC COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2017-2022)
Table 47. APAC COVID-19 Neutralizing Antibody Drugs Sales by Application (2017-2022) & (K Units)
Table 48. APAC COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2017-2022)
Table 49. Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2017-2022) & (K Units)
Table 50. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2017-2022)
Table 51. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2017-2022)
Table 53. Europe COVID-19 Neutralizing Antibody Drugs Sales by Type (2017-2022) & (K Units)
Table 54. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2017-2022)
Table 55. Europe COVID-19 Neutralizing Antibody Drugs Sales by Application (2017-2022) & (K Units)
Table 56. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of COVID-19 Neutralizing Antibody Drugs
Table 66. Key Market Challenges & Risks of COVID-19 Neutralizing Antibody Drugs
Table 67. Key Industry Trends of COVID-19 Neutralizing Antibody Drugs
Table 68. COVID-19 Neutralizing Antibody Drugs Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. COVID-19 Neutralizing Antibody Drugs Distributors List
Table 71. COVID-19 Neutralizing Antibody Drugs Customer List
Table 72. Global COVID-19 Neutralizing Antibody Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global COVID-19 Neutralizing Antibody Drugs Sales Market Forecast by Region
Table 74. Global COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas COVID-19 Neutralizing Antibody Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC COVID-19 Neutralizing Antibody Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe COVID-19 Neutralizing Antibody Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global COVID-19 Neutralizing Antibody Drugs Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share Forecast by Type (2023-2028)
Table 86. Global COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global COVID-19 Neutralizing Antibody Drugs Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share Forecast by Application (2023-2028)
Table 90. Global COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 92. Tychan Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Tychan COVID-19 Neutralizing Antibody Drugs Product Offered
Table 94. Tychan COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Tychan Main Business
Table 96. Tychan Latest Developments
Table 97. AstraZeneca Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. AstraZeneca COVID-19 Neutralizing Antibody Drugs Product Offered
Table 99. AstraZeneca COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. AstraZeneca Main Business
Table 101. AstraZeneca Latest Developments
Table 102. Molecular Partners
AG/诺华 Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Molecular Partners
AG/诺华 COVID-19 Neutralizing Antibody Drugs Product Offered
Table 104. Molecular Partners
AG/诺华 COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. Molecular Partners
AG/诺华 Main Business
Table 106. Molecular Partners
AG/诺华 Latest Developments
Table 107. Eli Lilly Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Eli Lilly COVID-19 Neutralizing Antibody Drugs Product Offered
Table 109. Eli Lilly COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Eli Lilly Main Business
Table 111. Eli Lilly Latest Developments
Table 112. Regeneron Pharmaceuticals Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Product Offered
Table 114. Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Regeneron Pharmaceuticals Main Business
Table 116. Regeneron Pharmaceuticals Latest Developments
Table 117. Abpro Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Abpro COVID-19 Neutralizing Antibody Drugs Product Offered
Table 119. Abpro COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Abpro Main Business
Table 121. Abpro Latest Developments
List of Figures
Figure 1. Picture of COVID-19 Neutralizing Antibody Drugs
Figure 2. COVID-19 Neutralizing Antibody Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global COVID-19 Neutralizing Antibody Drugs Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. COVID-19 Neutralizing Antibody Drugs Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of ACE2 Fusion Protein
Figure 10. Product Picture of Neutralizing Antibody
Figure 11. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type in 2021
Figure 12. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2017-2022)
Figure 13. COVID-19 Neutralizing Antibody Drugs Consumed in Hospital
Figure 14. Global COVID-19 Neutralizing Antibody Drugs Market: Hospital (2017-2022) & (K Units)
Figure 15. COVID-19 Neutralizing Antibody Drugs Consumed in Clinic
Figure 16. Global COVID-19 Neutralizing Antibody Drugs Market: Clinic (2017-2022) & (K Units)
Figure 17. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2017-2022)
Figure 18. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application in 2021
Figure 19. COVID-19 Neutralizing Antibody Drugs Revenue Market by Company in 2021 ($ Million)
Figure 20. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Company in 2021
Figure 21. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Geographic Region (2017-2022)
Figure 22. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Geographic Region in 2021
Figure 23. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2017-2022)
Figure 24. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country/Region in 2021
Figure 25. Americas COVID-19 Neutralizing Antibody Drugs Sales 2017-2022 (K Units)
Figure 26. Americas COVID-19 Neutralizing Antibody Drugs Revenue 2017-2022 ($ Millions)
Figure 27. APAC COVID-19 Neutralizing Antibody Drugs Sales 2017-2022 (K Units)
Figure 28. APAC COVID-19 Neutralizing Antibody Drugs Revenue 2017-2022 ($ Millions)
Figure 29. Europe COVID-19 Neutralizing Antibody Drugs Sales 2017-2022 (K Units)
Figure 30. Europe COVID-19 Neutralizing Antibody Drugs Revenue 2017-2022 ($ Millions)
Figure 31. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales 2017-2022 (K Units)
Figure 32. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue 2017-2022 ($ Millions)
Figure 33. Americas COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country in 2021
Figure 34. Americas COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country in 2021
Figure 35. United States COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 36. Canada COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 37. Mexico COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 38. Brazil COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 39. APAC COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region in 2021
Figure 40. APAC COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Regions in 2021
Figure 41. China COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 42. Japan COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 43. South Korea COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 44. Southeast Asia COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 45. India COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 46. Australia COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 47. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country in 2021
Figure 48. Europe COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country in 2021
Figure 49. Germany COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 50. France COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 51. UK COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 52. Italy COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 53. Russia COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 54. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country in 2021
Figure 55. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country in 2021
Figure 56. Egypt COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Africa COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 58. Israel COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 59. Turkey COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 60. GCC Country COVID-19 Neutralizing Antibody Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 61. Manufacturing Cost Structure Analysis of COVID-19 Neutralizing Antibody Drugs in 2021
Figure 62. Manufacturing Process Analysis of COVID-19 Neutralizing Antibody Drugs
Figure 63. Industry Chain Structure of COVID-19 Neutralizing Antibody Drugs
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets